Preventive Migraine Treatment

Neurologic Clinics

Volumn 27, Issue 2, 2009, Pages 429-443

  Silberstein, Stephen D ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Migraine; Prevention; Treatment

Indexed keywords

ACEBUTOLOL; ALPRENOLOL; AMITRIPTYLINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARBAMAZEPINE; CLOMIPRAMINE; DOXEPIN; FLUNARIZINE; FLUOXETINE; GABAPENTIN; METOPROLOL; NADOLOL; NICARDIPINE; NIMODIPINE; NORTRIPTYLINE; OPIATE; OXPRENOLOL; PINDOLOL; PLACEBO; PROPRANOLOL DERIVATIVE; PROTRIPTYLINE; SERTRALINE; TIMOLOL; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; VERAPAMIL;

ANOREXIA; ANXIETY; BEDTIME DOSAGE; BLURRED VISION; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG CAPSULE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; EXERCISE TOLERANCE; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; IMPOTENCE; INSOMNIA; LETHARGY; MEMORY DISORDER; MENTAL DISEASE; MIGRAINE; MIGRAINE AURA; MORBIDITY; MORNING DOSAGE; MYDRIASIS; NAUSEA; NERVOUSNESS; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PHYSICIAN; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; STROKE; SWEATING; TACHYCARDIA; TREATMENT DURATION; TREMOR; URINE RETENTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BOTULINUM TOXIN TYPE A; CALCIUM CHANNEL BLOCKERS; HUMANS; MIGRAINE DISORDERS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 61449097851     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2008.11.007     Document Type: Review

References (69)

1. Lipton R.B., and Silberstein S.D. Why study the comorbidity of migraine?. Neurology 44 (1994) 4-5
2. Silberstein S.D., Winner P.K., and Chmiel J.J. Migraine preventive medication reduces resource utilization. Headache: The Journal of Head and Face Pain 43 (2003) 171-178
3. Silberstein S.D. Headaches in pregnancy. Neurol Clin 22 (2004) 727-756
4. Lipton R.B., Diamond M., Freitag F., et al. Migraine prevention patterns in a community sample: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 45 (2005) 792-793 [abstract]
5. Silberstein S., Diamond S., Loder E., et al. Prevalence of migraine sufferers who are candidates for preventive therapy: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 45 (2005) 770-771 [abstract]
6. Tfelt-Hansen P. Prioritizing acute pharmacotherapy of migraine. In: Olesen J., Tfelt-Hansen P., and Welch K.M.A. (Eds). The headaches. 2nd edition (2000), Lippincott Williams & Wilkins, New York 453-456
7. Silberstein S.D. Migraine and pregnancy. Neurol Clin 15 (1997) 209-231
8. Olerud B., Gustavsson C.L., and Furberg B. Nadolol and propranolol in migraine management. Headache 26 (1986) 490-493
9. Ryan R.E., and Sudilovsky A. Nadolol: its use in the prophylactic treatment of migraine. Headache 23 (1983) 26-31
10. Ryan R.E. Comparative study of nadolol and propranolol in prophylactic treatment of migraine. Am Heart J 108 (1984) 1156-1159
11. Sudilovsky A., Stern M.A., and Meyer J.H. Nadolol: the benefits of an adequate trial duration in the prophylaxis of migraine. Headache 26 (1986) 325
12. Diener H.C., Agosti R., Allais G., et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6 (2007) 1054-1062
13. Gray RN, Goslin RE, McCrory DC, et al. Drug treatments for the prevention of migraine headache. Prepared for the Agency for Health Care Policy and Research, contact no. 290-94-2025. Available from the National Technical Information Service 1999; Accession No. 127953.
14. Silberstein S.D. Practice parameter-evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology for the United States Headache Consortium. Neurology 55 (2000) 754-762
15. Andersson K., and Vinge E. Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 39 (1990) 355-373
16. Koella W.P. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol 28 (1985) 55-63
17. Ramadan N.M. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 8 (2004) 91-95
18. Cortelli P., Sacquegna T., Albani F., et al. Propranolol plasma levels and relief of migraine. Arch Neurol 42 (1985) 46-48
19. Sudilovsky A., Elkind A.H., Ryan R.E., et al. Comparative efficacy of nadolol and propranolol in the management of migraine. Headache 27 (1987) 421-426
20. Tfelt-Hansen P., Standnes B., Kangasniemi P., et al. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 69 (1984) 1-8
21. Panerai A.E., Monza G., Movilia P., et al. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand 82 (1990) 34-38
22. Kishore-Kumar R., Max M.B., Schafer S.C., et al. Desipramine relieves post-herpetic neuralgia. Clin Pharmacol Ther 47 (1990) 305-312
23. Feinmann C. Pain relief by antidepressants: possible modes of action. Pain 23 (1985) 1-8
24. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin Proc 65 (1990) 1227-1236
25. Baldessarini R.J. Drugs and the treatment of psychiatric disorders. In: Gilman A.G., Rall T.W., Nies A.S., et al. (Eds). The pharmacological basis of therapeutics. 8th edition (1990), Pergamon, New York 383-435
26. Abramowicz M. Fluoxetine (Prozac) revisited. Med Lett Drugs Ther 32 (1990) 83-85
27. Silberstein S.D., Saper J.R., and Freitag F. Migraine: diagnosis and treatment. In: Silberstein S.D., Lipton R.B., and Dalessio D.J. (Eds). Wolff's headache and other head pain. 7th edition (2001), Oxford University Press, New York 121-237
28. Silberstein S.D., Lipton R.B., and Breslau N. Migraine: association with personality characteristics and psychopathology. Cephalalgia 15 (1995) 337-369
29. Mathew N.T., Saper J.R., Silberstein S.D., et al. Migraine prophylaxis with divalproex. Arch Neurol 52 (1995) 281-286
30. Lipton R.B., Gobel H., Wilks K., et al. Efficacy of petasites (an extract from Petasites rhizone) 50 and 75 mg for prophylaxis of migraine: results of a randomized, double-blind, placebo-controlled study. Neurology 58 (2002) A472 [abstract]
31. Bowden C.L., Brugger A.M., and Swann A.C. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 271 (1994) 918-924
32. Ozyalcin S.N., Talu G.K., Kiziltan E., et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45 (2005) 144-152
33. Bulut S., Berilgen M.S., Baran A., et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 107 (2004) 44-48
34. Greenberg D.A. Calcium channels in neurological disease. Ann Neurol 42 (1997) 275-282
35. Wauquier A., Ashton D., and Marranes R. The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 5 (1985) 119-120
36. Solomon G.D. Verapamil and propranolol in migraine prophylaxis: a double-blind crossover study. Headache 26 (1986) 325
37. Markley H.G., Cleronis J.C.D., and Piepko R.W. Verapamil prophylactic therapy of migraine. Neurology 34 (1984) 973-976
38. Riopelle R., and McCans J.L. A pilot study of the calcium channel antagonist diltiazem in migraine syndrome prophylaxis. Can J Neurol Sci 9 (1982) 269
39. Smith R., and Schwartz A. Diltiazem prophylaxis in refractory migraine. N Engl J Med 310 (1984) 1327-1328
40. Reveiz-Herault L., Cardona A.F., Ospina E.G., et al. [Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature]. Rev Neurol 36 (2003) 907-912 in Spanish
41. Hanston P.P., and Horn J.R. Drug interaction. Newsletter 5 (1985) 7-10
42. Rompel H., and Bauermeister P.W. Aetiology of migraine and prevention with carbamazepine (Tegretol). S Afr Med J 44 (1970) 75-80
43. Mathew N.T., Rapoport A., Saper J., et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41 (2001) 119-128
44. Coulam C.B., and Annagers J.R. New anticonvulsants reduce the efficacy of oral contraception. Epilepsia 20 (1979) 519-525
45. Klapper J.A. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17 (1997) 103-108
46. Klapper J.A. An open label crossover comparison of divalproex sodium and propranolol HCl in the prevention of migraine headaches. Headache Quarterly 5 (1995) 50-53
47. Freitag F.G., Collins S.D., Carlson H.A., et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. For the Depakote ER Migraine Study Group. Neurology 58 (2003) 1652-1659
48. Hering R., and Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12 (1992) 81-84
49. Jensen R., Brinck T., and Olesen J. Sodium valproate has prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 44 (1994) 241-244
50. Pellock J.M., and Willmore L.J. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 41 (1991) 961-964
51. Silberstein S.D. Divalproex sodium in headache-literature review and clinical guidelines. Headache 36 (1996) 547-555
52. Vainionpaa L.K., Rattya J., Knip M., et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 45 (1999) 444-450
53. Silberstein S.D., Neto W., Schmitt J., et al. Topiramate in the prevention of migraine headache: a randomized, double-blind, placebo-controlled, multiple-dose study. For the MIGR-001 Study Group. Arch Neurol 61 (2004) 490-495
54. Brandes J.L., Saper J.R., Diamond M., et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 291 (2004) 965-973
55. Diener H.C., Tfelt-Hansen P., Dahlof C., et al. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J Neurol 251 (2004) 943-950
56. Sachedo R.C., Reife R.A., Lim P., et al. Topiramate monotherapy for partial onset seizures. Epilepsia 38 (1997) 294-300
57. Thomson Healthcare. Physicians' desk reference. 57th edition (2003), Thomson PDR, Montvale (NJ)
58. Chen W.T., Fuh J.L., Lu S.R., et al. Persistent migrainous visual phenomena might be responsive to lamotrigine. Headache 41 (2001) 823-825
59. Steiner T.J., Findley L.J., and Yuen A.W. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 17 (1997) 109-112
60. Freitag F.G. Topiramate prophylaxis in patients suffering from migraine with aura: results from a randomized, double-blind, placebo-controlled trial. Advanced Studies in Medicine 3 (2003) S562-S564
61. Schrader H., Stovner L.J., Helde G., et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. Br Med J 322 (2001) 19-22
62. Tronvik E., Stovner L.J., Helde G., et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289 (2003) 65-69
63. Silberstein S.D., Mathew N., Saper J., et al. Botulinum toxin type A as a migraine preventive treatment. Headache 40 (2000) 445-450
64. Evers S., Vollmer-Haase J., Schwaag S., et al. Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 24 (2004) 838-843
65. Elkind A.H., O'Carroll P., Blumenfeld A., et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 7 (2006) 688-696
66. Saper JR, Mathew NT, Loder EW, et al. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med, In press.
67. Dodick D.W., Mauskop A., Elkind A.H., et al. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45 (2005) 315-324
68. Vogler B.K., Pittler M.H., and Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 18 (1998) 704-708
69. Schoenen J., Jacquy J., and Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50 (1998) 466-470